Generx (alferminogene tadenovec) / Gene Biotherapeutics, Dr. Reddy’s - LARVOL DELTA

"To many, many more. #CellRx #GeneRx" (@DrNikitaMehra)

"This perfectly sums up the memorable evening! On the discussion menu- Life, CARs, #GeneRx the sea, Goa & everything! So many new beginnings @CTCTC_tmc @ActImmuno @purwarrahul2 @GruppSteve @AkshaySharmaMD @AlbeenaDr @DrNikitaMehra @sadiyaa___ @shreshthashah97 @Ankesh1406" (@DrGauravNarula)

"& #GeneRx" (@DrNikitaMehra)

AFFIRM: Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia (clinicaltrials.gov) - P3 | N=160 | Not yet recruiting | Sponsor: Angionetics Inc. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Mar 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Cardiovascular • Myocardial Ischemia

"#tandem22 @ASTCT @ASGCTherapy Naldini discussing genotoxicity of retrovirus (risk of insertional mutagenesis & leukemia) lentiviral (clonal hematopoiesis) vectors used in #genetherapy #GeneRx" (@DrMiguelPerales)

Gene Therapies • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology

AFFIRM: Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia (clinicaltrials.gov) - P3; N=160; Not yet recruiting; Sponsor: Angionetics Inc.; Trial completion date: Dec 2022 ➔ Dec 2023; Trial primary completion date: Jun 2022 ➔ Mar 2023

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Myocardial Ischemia

"$RGRX RegeneRx Issues Year End Letter To Stockholders https://t.co/erN6LYxSxi" (@otcdynamics)

"$RGRX RegeneRx Closes Convertible Debt Financing https://t.co/M3J3xyHxXs" (@otcdynamics)

AFFIRM: Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia (clinicaltrials.gov) - P3; N=160; Not yet recruiting; Sponsor: Angionetics Inc.; N=320 ➔ 160

Enrollment change • Cardiovascular • Myocardial Ischemia

Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia (clinicaltrials.gov) - P3; N=320; Not yet recruiting; Sponsor: Angionetics Inc.; Trial completion date: Jun 2022 ➔ Dec 2022; Trial primary completion date: Jan 2022 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Gene Therapies • Ischemic stroke • Myocardial Ischemia • Reperfusion Injury

Thymosin β4 for the Treatment of Acute Stroke in Aged Rats. (PubMed, Neurosci Lett) - "...Rats were randomized to receive Tβ4 (12mg/kg, RegeneRx Biopharmaceuticals, Inc.) or control 24hrs after MCAo and then every 3days for 4 additional doses...In summary, Tβ4 treatment of stroke aged rats significantly reduces infarct volume compared to vehicle treated stroke, however, Tβ4 treatment did not show improvement in functional outcome, myelination or gliosis when compared to control. GFAP staining was significantly inversely correlated to improvement in the mNSS, suggesting that gliosis in the aged rat may be of benefit in improvement of functional outcome."

Journal • Biosimilar • Cardiovascular • Oncology • Solid Tumor • Venous Thromboembolism

Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia (clinicaltrials.gov) - P3; N=320; Not yet recruiting; Sponsor: Angionetics Inc.; Trial completion date: Jun 2021 ➔ Jan 2022; Initiation date: Jun 2018 ➔ Jun 2019; Trial primary completion date: Jun 2020 ➔ Jun 2021

Trial completion date • Trial initiation date • Trial primary completion date • Acute Coronary Syndrome • Biosimilar • Cardiovascular • Gene Therapies • Genetic Disorders • Reperfusion Injury

"ICYMI: @MDTechCouncil Ldrshp Dinner w/ @MDTEDCO CEO@FacilityLogix @pillsburylaw @MDBiz @MD_Stem_Cell @LearningUNDFTD @think_moco @UMBaltimore @GSKUS @ScheerPartners @RegeneRx_RGRX @ATT @evergreenadvise @Connectpreneur @emergentbiosolu @Precigen @MontgomeryCoMD @bearing_true" (@judycostello)

"#RegeneRx to Present at Fall Investor Summit on September 17 $RGRX https://t.co/x6DXm1JOCp" (@1stOncology)

"#RegeneRx Modifies September Conference Schedule $RGRX https://t.co/v0bUwR2PKc" (@1stOncology)

Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia (clinicaltrials.gov) - P3; N=320; Not yet recruiting; Sponsor: Angionetics Inc.; Trial completion date: Jan 2022 ➔ Jun 2022; Trial primary completion date: Jun 2021 ➔ Jan 2022

Clinical • Trial completion date • Trial primary completion date